Navigation Links
Reagan-Udall Foundation Announces New Board Chairman
Date:7/15/2014

WASHINGTON, July 15, 2014 /PRNewswire-USNewswire/ -- The Reagan-Udall Foundation for the FDA (RUF), an independent not-for-profit organization created by Congress for the purpose of advancing regulatory science critical to helping the U.S. Food and Drug Administration accomplish its mission, today announced that Mark C. Rogers, M.D., M.B.A., has been elected as Chairman of the RUF Board of Directors.

"It's an honor to welcome a physician, scientist, educator and executive as distinguished as Dr. Rogers to govern our Board," said Ellen V. Sigal, Ph.D., RUF Board Vice Chairman and Interim Board Chairman during the search. "Dr. Rogers brings with him decades of outstanding leadership in several fields of medicine and business. His experience and guidance will help to strengthen the Foundation's contribution to regulatory science."  Dr. Rogers succeeds Mark McClellan, M.D., Ph.D., the Board's founding Chairman, who continues to support the Foundation as a Board member leading the Innovation in Medical Evidence Development and Surveillance (IMEDS) program.

"It's a great privilege to be appointed Chair of this unique collaboration that has already contributed so much to advancing public health in just a few years," said Dr. Rogers. "I have great confidence that we'll continue to make important strides in accelerating regulatory science and ensuring FDA-regulated products that reach consumers continue to meet the highest standards of safety, efficacy and quality."

Following Dr. Rogers' appointment in 1977 as the first Director of the Pediatric Intensive Care Unit at The Johns Hopkins Hospital, he went on to be appointed Professor and Chair of the Department of Anesthesiology and Critical Care Medicine, then Associate Dean. He received his M.B.A. from the Wharton School of the University of Pennsylvania and, among other publications, authored what is now the international standard textbook in pediatric intensive care. Dr. Rogers has held several senior, pioneering leadership and foundational roles in biotechnology and biopharmaceutical companies and is involved in a number of public service activities.

The Reagan-Udall Foundation for the FDA is an independent 501(c)(3) not-for-profit organization created by Congress to advance the mission of the FDA by advancing regulatory science and research. With the ultimate goal of improving public health, the Foundation provides a unique opportunity to bring all parties to the table (FDA, patient groups, academia, other government entities and industry) to work together in a transparent way to create exciting new regulatory science.

 


'/>"/>
SOURCE Reagan-Udall Foundation for the FDA
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
7. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
8. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
9. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
10. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease
11. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017 Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens today announced ... Ms. Duseau succeeds Paul Thomas , the Company,s President and ... the Company,s Board of Directors.  The changes are effective today. ... Directors, effective today. ...
(Date:1/17/2017)... 17, 2017 Research and Markets has ... Diagnostics - Technologies, Markets and Companies" to their offering. ... ... remarkably during the past few years. More than 1,000 companies ... and 342 of these are profiled in the report along ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Pono Ola ... peaceful and healthy lifestyle, announced today the official launch of its much-anticipated Pono Board: ... mind. , In development for over a year, the patented Pono Board ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
Breaking Biology Technology:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
Breaking Biology News(10 mins):